China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase ... (separate prospectus supplement andaccomp...)

HOME >> MEDICINE >> NEWS

China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements

Date:8/11/2008

separate prospectus supplement and accompanying prospectus. The ADS purchasers will receive all of the proceeds from the sale of the purchased ADSs in the ADS offering. The Company will not receive any proceeds from the sale of the purchased ADSs in the ADS offering. The sale of the purchased ADSs is intended to facilitate privately negotiated transactions or short sales by which investors in the notes will hedge their investment in the notes. The closing of the notes offering is contingent upon the closing of the concurrent offering of purchased ADSs that will be initially offered at a fixed price, and the closing of the concurrent offering of purchased ADSs that will be initially offered at a fixed price is contingent upon the closing of the notes offering.

While the ordinary shares underlying the purchased ADSs will be considered issued and outstanding for purposes of Cayman Islands Companies Law, the Company believes that under U.S. GAAP currently in effect, the purchased ADSs will not be considered outstanding for the purpose of computing earnings per ADS because, pursuant to the ADS issuance and repurchase agreements, among other things, upon conversion, repurchase or payment at maturity of all of the notes, the ADS purchasers will be obligated to deliver to the Company a number of ADSs equal to the number of purchased ADSs, unless earlier delivered pursuant to the ADS issuance and repurchase agreements.

Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. Incorporated will act as underwriters for the notes offering and the ADS offering.

The notes offering and the ADS offering will be made under the Company's shelf registration statement filed with the Securities and Exchange Commission on August 11, 2008. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, and does not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale woul
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine news :

1. China Bio-Immunity Corporation Completes Share Exchange and Reverse Merger
2. China Healthcare Acquisition Corp Signs Definitive Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd.
3. UNC School of Social Work helps China tackle growing pains
4. Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics
5. China Shenghuo Pharmaceutical Retains Grayling Global As Investor Relations Counsel
6. China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008
7. China Medicine Corporation Obtains Australian Patent for rADTZ
8. China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company
9. AmeriCares Purchases 2nd BLU-MED Deployable Field Hospital for China Earthquake Relief
10. Closing coal-burning power plant in China and improved cognitive development in children
11. China Kangtai Cactus Biotech Inc. Launches Cactus Cattle Feed and Cactus Fish Feed

Post Your Comments:

China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase ...(separate prospectus supplement andaccomp...),Health